February 5, 2020
The Texas Drug Utilization Review Board met recently and made recommendations about drugs to be included on the Medicaid preferred drug list.
January 27, 2020
January 23, 2020
January 17, 2020
VDP will modify the Austedo prior authorization criteria on March 3. The criteria are included within the existing Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors criteria guide. The class includes Austedo, Xenazine and Ingrezza.
January 16, 2020
In 2019, the Texas State Legislature passed House Bill 2536 relating to drug cost transparency. It requires pharmaceutical drug manufacturers to report certain cost information on U.S. Food and Drug Administration-approved drugs sold in or into Texas.
January 15, 2020
VDP will revise the Allergen Extracts clinical prior authorization criteria on Feb. 24 to reflect the FDA guidance expanding the indication for Oralair.
VDP will implement the Rinvoq (upadacitinib) clinical prior authorization criteria on March 3.
January 10, 2020
January 2, 2020
Texas Health Steps provides resources for primary care providers and other health professionals, including a pharmacy continuing education course available for credit and two new quick courses:
Important reminders for pharmacy staff about Medicaid pharmacy benefits.
Pharmacy providers should expect increased controlled substance e-prescriptions and are encouraged to be certain that all staff are informed on accepting and dispensing these e-prescriptions, including CII e-prescription requirements.
November 18, 2019
The Texas Drug Utilization Review Board met recently to make recommendations about clinical prior authorizations and the preferred drug list.